Bill introduced
Lobbying filed by AMERICA'S HEALTH INSURANCE PLANS INC (AHIP)
Lobbying filed by PFIZER INC.
Lobbying filed by NOVARTIS
Lobbying filed by PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Committee on Health, Education, Labor, and Pensions. Hearings held.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
| Registrant | Client | Amount | Filed | Period | Issues |
|---|---|---|---|---|---|
| AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP) | AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | $4.8M | Apr 21, 2025 | 2025Q1 | HCRMMMINS |
| BRISTOL-MYERS SQUIBB COMPANY | BRISTOL-MYERS SQUIBB COMPANY | $4.8M | Jul 21, 2025 | 2025Q2 | HCRMMMTAX |
| PFIZER INC. |
The lobbying table lists Senate LDA quarterly reports (LD-2) that cite this bill by number and cover a quarter of the 119th Congress. An LD-2 names a bill as “H.R. 1234” with no Congress, so a report on another Congress, which can only concern a different bill with the same number, is left out, even when it was filed after this Congress began. The amount is what the registrant reported for the whole filing, across every issue on it, not spending on this bill. Official actions and the bill summary come from Congress.gov, and votes from the roll-call record. This page no longer pairs the bill with members' stock trades: matching lobbying clients to traded companies by name, and trades to a bill by date, is not something the records establish.
Lobbying filed by BRISTOL-MYERS SQUIBB COMPANY
| PFIZER INC. |
| $4.2M |
| Apr 21, 2025 |
| 2025Q1 |
BUDHCRMMM |
| NOVARTIS | NOVARTIS | $4.2M | Apr 21, 2025 | 2025Q1 | BUDCPTHCR |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | $4.1M | Apr 21, 2025 | 2025Q1 | MMMHCRPHA |
| AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP) | AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | $4.0M | Jul 21, 2025 | 2025Q2 | HCRMMMINS |
| THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | $3.5M | Apr 21, 2025 | 2025Q1 | MMMHCRDEF |
| CVS HEALTH (AND SUBSIDIARIES) | CVS HEALTH (AND SUBSIDIARIES) | $3.5M | Apr 21, 2025 | 2025Q1 | PHATAXMMM |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | $3.4M | Jul 21, 2025 | 2025Q2 | MMMHCRPHA |
| JOHNSON & JOHNSON SERVICES, INC. | JOHNSON & JOHNSON SERVICES INC | $3.3M | Apr 21, 2025 | 2025Q1 | PHASCITAX |
| SANOFI US SERVICES INC. | SANOFI US SERVICES INC | $2.5M | Apr 21, 2025 | 2025Q1 | MANHCRMMM |
| ABBVIE, INC. | ABBVIE INC. | $2.1M | Apr 21, 2025 | 2025Q1 | CPTHCRMMM |
| AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC. | AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC | $2.0M | Apr 21, 2025 | 2025Q1 | HCRTAXTOB |
| THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | $1.9M | Jul 21, 2025 | 2025Q2 | MMMHCRDEF |
| VERTEX PHARMACEUTICALS INCORPORATED | VERTEX PHARMACEUTICALS INCORPORATED | $1.6M | Apr 18, 2025 | 2025Q1 | MMMTAXBUD |
| GSK (FKA GLAXOSMITHKLINE INC.) | GSK (FKA GLAXOSMITHKLINE INC.) | $1.5M | Jul 21, 2025 | 2025Q2 | BUDCPTHCR |
| ABBVIE, INC. | ABBVIE INC. | $1.2M | Jul 21, 2025 | 2025Q2 | CPTHCRMMM |
| VERTEX PHARMACEUTICALS INCORPORATED | VERTEX PHARMACEUTICALS INCORPORATED | $1.1M | Jul 16, 2025 | 2025Q2 | HCRMMMTAX |
| SANOFI US SERVICES INC. | SANOFI US SERVICES INC | $1.1M | Jul 21, 2025 | 2025Q2 | HCRMMMTRD |
| JOHNSON & JOHNSON SERVICES, INC. | JOHNSON & JOHNSON SERVICES INC | $1.0M | Jul 21, 2025 | 2025Q2 | HCRBUDCPT |
| EMD SERONO, INC. | EMD SERONO INC | $910.0K | Jul 21, 2025 | 2025Q2 | HCRMMMPHA |
| EMD SERONO, INC. | EMD SERONO INC | $900.0K | Apr 21, 2025 | 2025Q1 | SCITRDHCR |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | BIOTECHNOLOGY INNOVATION ORGANIZATION | $890.0K | Apr 21, 2025 | 2025Q1 | AGRANIBUD |
| NOVARTIS | NOVARTIS | $880.0K | Jul 21, 2025 | 2025Q2 | BUDCPTHCR |
| GSK (FKA GLAXOSMITHKLINE INC.) | GSK (FKA GLAXOSMITHKLINE INC.) | $800.0K | Apr 21, 2025 | 2025Q1 | BUDCPTHCR |
| ASSOCIATION FOR CLINICAL ONCOLOGY | ASSOCIATION FOR CLINICAL ONCOLOGY | $650.0K | Jul 17, 2025 | 2025Q2 | MMMHCRTOB |
| AMERICAN ACADEMY OF OPHTHALMOLOGY | AMERICAN ACADEMY OF OPHTHALMOLOGY | $427.6K | Apr 21, 2025 | 2025Q1 | HCRVETDEF |
| CYSTIC FIBROSIS FOUNDATION | CYSTIC FIBROSIS FOUNDATION | $300.0K | Jul 21, 2025 | 2025Q2 | HCRINSBUD |
| ASSOCIATION FOR CLINICAL ONCOLOGY | ASSOCIATION FOR CLINICAL ONCOLOGY | $250.0K | Apr 17, 2025 | 2025Q1 | MMMHCRTOB |
| AMERICAN ACADEMY OF OPHTHALMOLOGY | AMERICAN ACADEMY OF OPHTHALMOLOGY | $207.3K | Jul 21, 2025 | 2025Q2 | HCRVETDEF |
| CYSTIC FIBROSIS FOUNDATION | CYSTIC FIBROSIS FOUNDATION | $200.0K | Apr 21, 2025 | 2025Q1 | HCRINSBUD |
| AMERICAN COLLEGE OF RHEUMATOLOGY | AMERICAN COLLEGE OF RHEUMATOLOGY | $180.0K | Jul 21, 2025 | 2025Q2 | HCRBUDMMM |
| EPILEPSY FOUNDATION | EPILEPSY FOUNDATION | $160.0K | Apr 18, 2025 | 2025Q1 | BUDHCRCIV |
| THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN | THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN | $110.0K | Apr 21, 2025 | 2025Q1 | BUDINSMMM |
| TODD STRATEGY GROUP | ALEXION PHARMACEUTICALS, INC. | $80.0K | Jul 19, 2025 | 2025Q2 | MMMHCR |
| AMERICAN COLLEGE OF RHEUMATOLOGY | AMERICAN COLLEGE OF RHEUMATOLOGY | $80.0K | Apr 21, 2025 | 2025Q1 | HCRBUDMMM |
| TODD STRATEGY GROUP | ALEXION PHARMACEUTICALS, INC. | $80.0K | Apr 21, 2025 | 2025Q1 | MMMHCR |
| ARTHRITIS FOUNDATION | ARTHRITIS FOUNDATION | $75.0K | Jul 17, 2025 | 2025Q2 | MMMHCRBUD |
| ARTHRITIS FOUNDATION | ARTHRITIS FOUNDATION | $75.0K | Apr 18, 2025 | 2025Q1 | MMMHCRBUD |
| THE KPM GROUP DC LLC | THE HS COALITION | $70.0K | Jul 17, 2025 | 2025Q2 | PHA |
| EMERGENT STRATEGIES | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | $60.0K | Jul 21, 2025 | 2025Q2 | PHA |
| EPILEPSY FOUNDATION | EPILEPSY FOUNDATION | $60.0K | Jul 21, 2025 | 2025Q2 | BUDHCRCIV |
| TODD STRATEGY GROUP | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $60.0K | Jul 20, 2025 | 2025Q2 | PHAMMM |
| TODD STRATEGY GROUP | JOHNSON & JOHNSON SERVICES, INC. | $60.0K | Jul 19, 2025 | 2025Q2 | HCR |
| THE NICKLES GROUP, LLC | UCB, INC. | $60.0K | Jul 10, 2025 | 2025Q2 | MMMTAXHCR |
| TODD STRATEGY GROUP | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $60.0K | Apr 21, 2025 | 2025Q1 | MMMPHA |
| TODD STRATEGY GROUP | JOHNSON & JOHNSON SERVICES, INC. | $60.0K | Apr 21, 2025 | 2025Q1 | HCR |
| EMERGENT STRATEGIES | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | $60.0K | Apr 21, 2025 | 2025Q1 | PHA |
| THE NICKLES GROUP, LLC | UCB, INC. | $60.0K | Apr 21, 2025 | 2025Q1 | MMMTAXHCR |
| TODD STRATEGY GROUP | EMD SERONO INC. | $50.0K | Jul 19, 2025 | 2025Q2 | PHAHCR |
| ARTEMIS POLICY GROUP LLC | NATIONAL BLEEDING DISORDER FOUNDATION (FKA NATIONAL HEMOPHILIA FOUNDATION) | $50.0K | Jul 18, 2025 | 2025Q2 | MMMHCRINS |
| TODD STRATEGY GROUP | EMD SERONO INC. | $50.0K | Apr 21, 2025 | 2025Q1 | PHAHCR |
| TODD STRATEGY GROUP | MERCK & CO., INC. | $40.0K | Jul 20, 2025 | 2025Q2 | HCRMMM |
| ARTEMIS POLICY GROUP LLC | SUSAN G. KOMEN | $40.0K | Jul 18, 2025 | 2025Q2 | BUDINSMMM |
| THE KPM GROUP DC LLC | ASTRIA THERAPEUTICS, INC. | $40.0K | Jul 17, 2025 | 2025Q2 | PHA |
| VENABLE LLP | PATIENT ACCESS NETWORK FOUNDATION | $40.0K | Jul 3, 2025 | 2025Q2 | HCR |
| ARTEMIS POLICY GROUP LLC | SUSAN G. KOMEN | $40.0K | Apr 21, 2025 | 2025Q1 | BUDINSMMM |
| THE KPM GROUP DC LLC | ASTRIA THERAPEUTICS, INC. | $40.0K | Apr 21, 2025 | 2025Q1 | PHA |
| TODD STRATEGY GROUP | MERCK & CO., INC. | $40.0K | Apr 21, 2025 | 2025Q1 | HCRMMM |
| LMH STRATEGIC SOLUTIONS | GLAXOSMITHKLINE LLC | $40.0K | Apr 18, 2025 | 2025Q1 | HCRPHA |
| VENABLE LLP | PATIENT ACCESS NETWORK FOUNDATION | $40.0K | Apr 7, 2025 | 2025Q1 | HCR |
| THE ALS ASSOCIATION | THE ALS ASSOCIATION | $30.0K | Jul 22, 2025 | 2025Q2 | VETTAXHCR |
| THE ALS ASSOCIATION | THE ALS ASSOCIATION | $30.0K | Apr 20, 2025 | 2025Q1 | BUDHCRMMM |
| SPANGLER STRATEGIES LLC | AMERICAN BANKERS ASSOCIATION | $20.0K | Jul 17, 2025 | 2025Q2 | TAXCSP |
| SPANGLER STRATEGIES LLC | AMERICAN BANKERS ASSOCIATION | $20.0K | Apr 18, 2025 | 2025Q1 | TAXCSP |
| NATIONAL PSORIASIS FOUNDATION | NATIONAL PSORIASIS FOUNDATION | Undisclosed | Jun 2, 2025 | 2025Q1 | HCRMMM |